Literature DB >> 21920474

A novel polyclonal antibody library for expression profiling of poorly characterized, membrane and secreted human proteins.

Renata Grifantini1, Massimiliano Pagani, Andrea Pierleoni, Alberto Grandi, Matteo Parri, Susanna Campagnoli, Piero Pileri, Davide Cattaneo, Elena Canidio, Angela Pontillo, Elisa De Camilli, Alberto Bresciani, Federica Marinoni, Eros Pedrazzoli, Renzo Nogarotto, Sergio Abrignani, Giuseppe Viale, Paolo Sarmientos, Guido Grandi.   

Abstract

The YOMICS™ antibody library (http://www.yomics.com/) presented in this article is a new collection of 1559 murine polyclonal antibodies specific for 1287 distinct human proteins. This antibody library is designed to target marginally characterized membrane-associated and secreted proteins. It was generated against human proteins annotated as transmembrane or secreted in GenBank, EnsEMBL, Vega and Uniprot databases, described in no or very few dedicated PubMed-linked publications. The selected proteins/protein regions were expressed in E. coli, purified and used to raise antibodies in the mouse. The capability of YOMICS™ antibodies to specifically recognize their target proteins either as recombinant form or as expressed in cells and tissues was confirmed through several experimental approaches, including Western blot, confocal microscopy and immunohistochemistry (IHC). Moreover, to show the applicability of the library for biomarker investigation by IHC, five antibodies against proteins either known to be expressed in some cancers or homologous to tumor-associated proteins were tested on tissue microarrays carrying tumor and normal tissues from breast, colon, lung, ovary and prostate. A consistent differential expression in cancer was observed. Our results indicate that the YOMICS™ antibody library is a tool for systematic protein expression profile analysis that nicely complements the already available commercial antibody collections.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21920474     DOI: 10.1016/j.jprot.2011.08.018

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  7 in total

1.  Identification of new autoantigens by protein array indicates a role for IL4 neutralization in autoimmune hepatitis.

Authors:  Chiara Zingaretti; Milena Arigò; Angela Cardaci; Monica Moro; Mariacristina Crosti; Antonella Sinisi; Elisa Sugliano; Cristina Cheroni; Francesco Marabita; Renzo Nogarotto; Raoul Jean Pierre Bonnal; Paolo Marcatili; Maurizio Marconi; Annalinda Zignego; Paolo Muratori; Pietro Invernizzi; Piero Colombatto; Maurizia Brunetto; Ferruccio Bonino; Raffaele De Francesco; Jens Geginat; Massimiliano Pagani; Luigi Muratori; Sergio Abrignani; Mauro Bombaci
Journal:  Mol Cell Proteomics       Date:  2012-09-20       Impact factor: 5.911

2.  Identification of new hematopoietic cell subsets with a polyclonal antibody library specific for neglected proteins.

Authors:  Monica Moro; Mariacristina Crosti; Pasquale Creo; Pierangela Gallina; Serena Curti; Elisa Sugliano; Rossana Scavelli; Davide Cattaneo; Elena Canidio; Maurizio Marconi; Paolo Rebulla; Paolo Sarmientos; Giuseppe Viale; Massimiliano Pagani; Sergio Abrignani
Journal:  PLoS One       Date:  2012-04-04       Impact factor: 3.240

3.  Two of Them Do It Better: Novel Serum Biomarkers Improve Autoimmune Hepatitis Diagnosis.

Authors:  Saveria Mazzara; Antonia Sinisi; Angela Cardaci; Riccardo Lorenzo Rossi; Luigi Muratori; Sergio Abrignani; Mauro Bombaci
Journal:  PLoS One       Date:  2015-09-16       Impact factor: 3.240

4.  Negatively charged AuNP modified with monoclonal antibody against novel tumor antigen FAT1 for tumor targeting.

Authors:  Li Fan; Susanna Campagnoli; Hong Wu; Alberto Grandi; Matteo Parri; Elisa De Camilli; Guido Grandi; Giuseppe Viale; Piero Pileri; Renata Grifantini; Chaojun Song; Boquan Jin
Journal:  J Exp Clin Cancer Res       Date:  2015-09-15

5.  FAT1: a potential target for monoclonal antibody therapy in colon cancer.

Authors:  Piero Pileri; Susanna Campagnoli; Alberto Grandi; Matteo Parri; Elisa De Camilli; Chaojun Song; Luisa Ganfini; Aurelien Lacombe; Ilaria Naldi; Paolo Sarmientos; Caterina Cinti; Boquan Jin; Guido Grandi; Giuseppe Viale; Luigi Terracciano; Renata Grifantini
Journal:  Br J Cancer       Date:  2016-06-21       Impact factor: 7.640

6.  TCTN2: a novel tumor marker with oncogenic properties.

Authors:  David Cano-Rodriguez; Susanna Campagnoli; Alberto Grandi; Matteo Parri; Elisa De Camilli; Chaojun Song; Boquan Jin; Aurelien Lacombe; Andrea Pierleoni; Mauro Bombaci; Chiara Cordiglieri; Marcel Hj Ruiters; Giuseppe Viale; Luigi Terracciano; Paolo Sarmientos; Sergio Abrignani; Guido Grandi; Piero Pileri; Marianne G Rots; Renata Grifantini
Journal:  Oncotarget       Date:  2017-08-24

7.  ERMP1, a novel potential oncogene involved in UPR and oxidative stress defense, is highly expressed in human cancer.

Authors:  Alberto Grandi; Alice Santi; Susanna Campagnoli; Matteo Parri; Elisa De Camilli; Chaojun Song; Boquan Jin; Aurelien Lacombe; Serenella Castori-Eppenberger; Paolo Sarmientos; Guido Grandi; Giuseppe Viale; Luigi Terracciano; Paola Chiarugi; Piero Pileri; Renata Grifantini
Journal:  Oncotarget       Date:  2016-09-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.